Aldeyra Therapeutics Inc at Jefferies Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kelly Shi - Jefferies Group LLC - Analyst : And so maybe we can talk about reproxalap first, which is the investor's key focus. We have a big product data coming by the end of the year. And also target a big market of dry eye. So maybe you can tell us how is the review process progressing so far? And have you had a mid-cycle review meeting? And if so, what is the outcome?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great.

Question: Kelly Shi - Jefferies Group LLC - Analyst : Okay, terrific. And you have previously mentioned a partnership will be ideal for commercial light -- commercialize in dry eye. So how should we think about the timing and -- first, is this still like in our plan? And also, if yes answer, what is the ideal partner look like in your mind?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Okay, great. And what kind of label do you anticipate given that you have showed a broad range of sign and the symptom endpoint data? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 09, 2023 / 1:30PM, ALDX.OQ - Aldeyra Therapeutics Inc at Jefferies Healthcare Conference

Question: Kelly Shi - Jefferies Group LLC - Analyst : Okay, great. And before we move to next, as I said probably -- briefly, conjunctivitis, the timing of Phase 3 data and the next step.

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great. And now moving to 2191, which is intravitreal, my third track set. And -- so in true, not only you have data catalysts, you also have a regulatory catalyst that actually -- this could be our first commercial product from Aldeyra. And it is for treating primary vitreoretinal lymphoma, PVRIL. Maybe you could help us to understand the unmet needs there and market potential. And before that, maybe I should ask you how confident are you for a timely approval?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great. And in June, you have multiple data presentations. And also, after this area, you plan to incur press release altogether or separately to keep us busy?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Okay. And yeah, we did not forget Oral RASP 629. So for your pipeline, not only you have multiple assets each asset that you have, multiple indications to pursue. So for this Oral RASP, what can you tell us what had clinical trials under development? And also, what is the plan for the data release?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great, and there is a good level of interest in your chronic cough Phase 2 data. You just said, in near term, given the recent deal on BELLUS and -- how should we think about this data set in terms of patient number and efficacy metrics you'll be reporting? And also compared to competitor candidate such as the P2X3 receptor activator, how are you thinking about positioning of 629?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great. And you recently announced the further expansion of your RASP modulation pipeline with two new candidates, ADX-246, which is an oral agent OF systemic immune-mediated disease and ADX-248, which is intravitreal injection for GA. Maybe you can help us to understand, you already have a stray assets in relatively mid-to-late stage. And for very broad indications, so what actually drives you to move to new molecules?

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great. Lastly, can you remind us your cash position and the runway?

Question: Kelly Shi - Jefferies Group LLC - Analyst : And the cash runway. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 09, 2023 / 1:30PM, ALDX.OQ - Aldeyra Therapeutics Inc at Jefferies Healthcare Conference

Question: Kelly Shi - Jefferies Group LLC - Analyst : Great. As always, thanks for a terrific discussion. And thanks, everyone, for attending this session.